Attorney Docket # 4061-33PUS

Express Mail #EV857194359US Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re National Phase PCT Application of

Silvo ZUPANCIC et al.

Int'l PCT Serial No.: PCT/EP2004/014102ï□

Int'l Filing Date::

December 10, 2004

For:

Processes for Preparing Venlafaxine and

Venlafaxine Hydrochloride of Form I

INFORMATION DISCLOSURE STATEMENT

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SIR:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO/SB/08a. Copies of the listed documents are also enclosed.

In accordance with 37 C.F.R §§1.97(g) and (h), the filing of this Information Disclosure Statement should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserve(s) the right to prove that the date of publication is in fact different.

It is respectfully requested that the above information be considered by the Examiner and that the copy of the enclosed Form PTO/SB/08a be returned indicating that such information has been considered.

> Respectfully submitted, COHEN, PONTANI, LIEBERMAN & PAVANE LLP

Kent H. Cheng Reg. No. 33,849

551 Fifth Avenue, Suite 1210 New York, New York 10176 (212) 687-2770

Dated: June 16, 2006

IAPZU Rec'd PCT/PTO 16 JUN 2006

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/PTO		Complete if Known		
		Application Number	10/583439	
INFO	DRMATION DISCLOSURE	Filing Date	101707477	
-	TEMENT BY APPLICANT	First Named Inventor	Silvo ZUPANCIC	
SIA	(Use as many sheets as necessary)	Art Unit		
		Examiner Name		
Sheet	1 of 2	Attorney Docket	4061-33PUS	
		Number		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Document Number Number-Kind-Code 2 (if known)	Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

	_	FO	REIGN PAT	ENT DOCUMENTS		
Examiner	Cite	Foreign Patent	Publication	Name of Patentee or	Pages, Columns,	T ⁶
Initials*	No.	Document	Date	Applicant of Cited	Lines, Where	
	1	Country Code ³⁻	MM-DD-	Document	Relevant Passages	
		Number ⁴ -Kind-	YYYY		or Relevant	
		Code 5 (if known			Figures Appear	
		EP 0112669	07/04/984	American Home		
				Products Corp.		
		EP 0797991	10/01/1997	American Home		
				Products		
		WO 02/45658	06/13/2002	Teva Pharmaceutical		
				Industries		
		WO 02/50017	06/27/2002	CIBA Specialty		
				Chemicals Holdings		
		WO 03/050074	06/19/2003	Cadila Healthcare		
				Limited		

Examiner	Date
Signature	Considered
	00.03.44.45

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number AP20 Rec c PCT/PTO 1 6 . IIIN 2006

	- 10 00N =00					
Substitute for Form 1449/PTO				Complete if Known		
				Application Number	10/583439	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	101707477	
				First Named Inventor	Silvo ZUPANCIC	
				Art Unit		
	(Ose as many	3110013 43 110		Examiner Name		
Sheet	2	of	2	Attorney Docket	4061-33PUS	
				Number		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	T ²
	1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date,	
		page(s), volume-issue number(s), publisher, city and/or country where published.	
		John P. Yardley, et al., 2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine	-
		Derivatives: Synthesis and Antidepressant Activity, J. Med. Chem., Vol. 33, p. 2899-2905 (1990).	
			<u> </u>
	<u> </u>		

Examiner Signature	Date Considered	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.